Precipio, Inc. (PRPO) AI Stock Analysis
PRPO AI stock analysis summary
AI ResearchPrecipio, Inc. is a healthcare diagnostics provider focused on advanced blood cancer testing products and services. The company grew annual revenue by 50.6% in FY2025 to $24.0M while narrowing its net loss to -$363,000. Trailing twelve month revenue reached $27.2M, though operating margin remained negative at -8.5%.
- Market cap
- $38.3M
- Revenue (TTM)
- $27.2M
- P/E
- — fwd 15.4x
- 1Y return
- 14.6% S&P 500 16.8%
- Avg. target
- $19.00 -11.1% vs last close
Bull case
- Precipio generated 50.6% revenue growth in FY2025 to reach $24.0M, supported by a 5-year revenue CAGR of 31.6%.
- Free cash flow improved into positive territory at $359,000 in FY2025 alongside operating cash flow of $685,000.
- The stock trades at a price-to-sales multiple of 1.4x, well below the US-listed Healthcare peer median of 4.1x.
Bear case
- The mean analyst price target of $19.00 indicates an 11.1% discount to the last close of $21.38.
- The company remains unprofitable on a trailing basis, reporting a net profit margin of -4.5% and an operating margin of -8.5%.
- Over the past five years, the company expanded its share count by 57.4%, while the stock declined 58.3%.
What Precipio does
Precipio, Inc. is a healthcare solutions provider based in New Haven, Connecticut, specializing in diagnostic products, reagents, and services primarily within the United States. The company focuses on advanced diagnostic blood cancer testing services using proprietary technologies. Key offerings include IV-Cell, a specialized cell culture media that facilitates the simultaneous culturing of four hematopoietic cell lineages, and HemeScreen, a comprehensive suite of genetic diagnostic panels for assessing hematologic malignancies. Precipio also utilizes patented ICE-COLD PCR technology to enhance the sensitivity of molecular tests, offers COVID-19 antibody tests, and collaborates with academic institutions specializing in cancer research.
Growth and profitability
Between FY2020 and FY2025, Precipio achieved a 5-year revenue CAGR of 31.6%. Revenue expanded from $8.8M in FY2021 to $16.0M in FY2024 and reached $24.0M in FY2025, representing 50.6% annual growth. Gross margin improved from 27.0% in FY2021 to 44.5% in FY2025. Operating margin also improved significantly, rising from -108.6% in FY2021 to -5.0% in FY2025. Net losses narrowed from -$8.6M in FY2021 and -$12.2M in FY2022 to -$363,000 in FY2025. For the latest quarter ended June 30, 2026, quarterly revenue grew 24.2% year-over-year, bringing trailing twelve month revenue to $27.2M with a net profit margin of -4.5%.
Balance sheet and cash flow
As of June 30, 2026, Precipio held $3.1M in cash and short-term investments against total debt of $3.3M, yielding net debt of $261,000. The company reported a current ratio of 1.77, total assets of $21.3M, and shareholders' equity of $14.8M, resulting in a debt-to-equity ratio of 0.23. Cash generation has turned positive, with operating cash flow reaching $685,000 and free cash flow at $359,000 in FY2025 after capital expenditures of $326,000. Over the past five years, the share count increased by 57.4%.
Valuation and performance
Precipio has a market capitalization of $38.3M and an enterprise value of $43.4M. The stock trades at a forward P/E of 15.4x, lower than the 17.3x median of its US-listed Healthcare peers. Its price-to-sales ratio stands at 1.4x, compared to the peer median of 4.1x, while its EV/EBITDA multiple of 64.4x sits well above the peer median of 12.0x. Over the past year, the stock gained 14.6%, trailing the S&P 500 return of 16.8%. Over a 5-year period, the stock fell 58.3% compared to an 83.0% gain for the S&P 500.
What analysts expect
Wall Street tracking for Precipio includes a mean price target of $19.00, which sits 11.1% below the last closing price of $21.38 recorded on October 16, 2026. The company beat EPS estimates in 2 of the last 4 quarters and reported an EPS of -$0.64 over the trailing twelve months. The company's next earnings date is scheduled for November 13, 2026.
Key risks and what to watch
- Long-term share dilution is evident from a 57.4% increase in share count over 5 years.
- Liquidity is tight with cash and short-term investments of $3.1M against total debt of $3.3M.
- The company's EV/EBITDA multiple of 64.4x is elevated relative to the US-listed Healthcare peer median of 12.0x.
- Precipio displays heightened volatility with a beta of 1.30 and trades 15.2% below its 200-day moving average.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this PRPO AI stock analysis
This page is an AI-written research summary of Precipio, Inc. (PRPO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: PRPO income statement, PRPO balance sheet, PRPO key metrics, PRPO chart. See the PRPO stock overview for the latest quote and news.
PRPO AI stock analysis FAQ
What was Precipio's revenue growth in FY2025?
Precipio reported revenue of $24.0M in FY2025, which represented a 50.6% increase compared to FY2024.
Is Precipio profitable?
Precipio is not yet profitable, recording a net loss of -$363,000 in FY2025 and a trailing twelve month net profit margin of -4.5%.
What is Precipio's cash and debt position?
As of June 30, 2026, the company held $3.1M in cash and short-term investments and $3.3M in total debt, resulting in net debt of $261,000.
What do analysts target for PRPO stock?
Analysts have established a mean price target of $19.00, representing an 11.1% decline from the last closing price of $21.38 on October 16, 2026.